Is Gland Pharma overvalued or undervalued?

As of 4 November 2025, Gland Pharma's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its perceived value. The company is currently considered overvalued. Key ratios include a PE ratio of 39.73, an EV to EBITDA of 4.64, and a PEG ratio of 2.78, which suggest that the stock is trading at a premium compared to its earnings growth potential.
In comparison to its peers, Gland Pharma's PE ratio is higher than Sun Pharma's 35.41 and significantly above Cipla's attractive valuation at 22.35. Additionally, Gland's EV to EBITDA is lower than that of Divi's Lab at 57.75, but still reflects a higher valuation compared to more attractively priced peers like Zydus Lifesciences at 13.21. Notably, Gland Pharma has outperformed the Sensex over the past year with a return of 18.94% compared to the Sensex's 5.94%, yet this does not mitigate its current overvaluation status.